Liquidia - LQDA Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LQDA shares.
View LQDA analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 12 month target prices for Liquidia's stock. Their LQDA share price forecasts range from $3.00 to $20.00. On average, they expect the company's stock price to reach $13.60 in the next year. This suggests a possible upside of 97.7% from the stock's current price.
View analysts price targets for LQDA or view top-rated stocks among Wall Street analysts.

Liquidia's stock was trading at $6.37 at the beginning of the year. Since then, LQDA stock has increased by 8.0% and is now trading at $6.88.
View the best growth stocks for 2023 here.

Liquidia saw a drop in short interest during the month of February. As of February 28th, there was short interest totaling 2,390,000 shares, a drop of 8.8% from the February 13th total of 2,620,000 shares. Based on an average trading volume of 505,800 shares, the days-to-cover ratio is currently 4.7 days.
View Liquidia's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our LQDA earnings forecast.

Liquidia Co. (NASDAQ:LQDA) released its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. The firm earned $3.18 million during the quarter, compared to the consensus estimate of $2.48 million.

ETFs with the largest weight of Liquidia (NASDAQ:LQDA) stock in their portfolio include SPDR S&P Kensho New Economies Composite ETF (KOMP), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Principal Healthcare Innovators ETF (BTEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA).

(LQDA) raised $50 million in an initial public offering (IPO) on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Liquidia trades on the NASDAQ under the ticker symbol "LQDA."

Liquidia's stock is owned by many different retail and institutional investors. Top institutional shareholders include Caligan Partners LP (15.78%), Eversept Partners LP (2.00%), Geode Capital Management LLC (1.37%), Opaleye Management Inc. (0.87%), Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.84%) and Two Sigma Investments LP (0.77%). Insiders that own company stock include Arthur S Kirsch, Caligan Partners Lp, Eshelman Ventures, Llc, Michael Kaseta, Paul B Manning, Robert A Lippe, Roger Jeffs, Russell Schundler and Scott Moomaw.
View institutional ownership trends.

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LQDA stock can currently be purchased for approximately $6.88.

Liquidia (NASDAQ:LQDA) has a market capitalization of $443.76 million and generates $15.94 million in revenue each year. The company earns $-41,010,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

Liquidia's mailing address is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. The official website for the company is www.liquidia.com. The company can be reached via phone at (919) 328-4400 or via email at ir@liquidia.com.